

2/40

LUV-SUV #2		Hepatic mRNA content (pg/ug)							
Rabbit #	Treatment	CETP	HMG-CoA R	LDL R	17 α -hydroxylase	LDL ChE, day 1	LDL ChE, day 3	LDL ChE, day 5	LDL ChE, day 6
1	(A) PBS	2.87	0.54	4.27	0.56	7.4	7.1	5.2	6.5
2	(A) PBS	5.63	0.55	5.38	0.39	18.1	11.8	6.2	9.7
3	(A) PBS	5.34	0.39	8.93	0.74	8.5	8.9	4.4	8.7
4	(A) PBS	5.04	0.55	5.49	0.82	14.1	14.1	6.8	8.6
	Mean	4.72	0.51	6.02	0.83	11.53	10.48	6.15	8.38
	SEM	0.63	0.04	1.01	0.10	2.12	1.55	0.98	0.67
5	(B) LUV	3.15	0.58	7.23	0.63	25.3	14.9	13.6	10.5
6	(B) LUV	3.02	0.47	8.15	0.58	14.0	15.9	10.8	8.2
7	(B) LUV	2.52	0.58	4.81	0.83	28.3	22.5	21.3	22.4
8	(B) LUV	2.68	0.58	7.37	0.94	17.5	21.8	13.4	9.5
	Mean	2.84	0.55	8.69	0.75	21.28	16.78	14.78	12.85
	SEM	0.15	0.03	0.72	0.08	3.33	1.96	2.27	3.28
	t vs. PBS	2.910	0.939	0.703	0.919	2.473	3.318	3.506	1.275
13	SUV + LUV	3.18	0.50	5.28	0.51	11.9	34.0	20.1	22.2
10	(C) SUV	5.64	0.38	3.98	0.30	21.1	45.3	15.3	46.3
11	(C) SUV	3.39	0.29	3.67	0.42	10.0	36.3	59.6	42.7
12	(C) SUV	3.00	0.13	3.34	0.63	17.8	31.8	45.5	22.3
	Mean w/o #13	4.01	0.27	3.66	0.45	16.30	37.80	40.13	37.10
	SEM w/o #13	0.02	0.07	0.18	0.10	3.28	3.97	13.07	7.47
	t vs. PBS	0.686	2.903	2.295	1.304	1.220	6.414	2.594	3.628
	t vs. LUV	1.397	3.660	4.328	2.301	1.963	4.296	1.912	2.98
	Mean w/ #13	3.80	0.33	4.07	0.47	15.20	38.86	35.13	33.38
	SEM w/ #13	0.62	0.06	0.42	0.07	2.57	2.96	10.51	8.48
	t vs. PBS	1.041	2.091	1.781	1.369	1.103	7.890	2.748	3.848
	t vs. LUV	1.512	2.763	3.369	2.554	1.445	8.085	1.893	2.856

FIG. 2

3/40

Plasma LDL cholesteryl ester concentrations
in response to injections of LUVs, SUVs, or saline





FIG. 3

4/40

Plasma LDL cholesteryl ester concentrations
in response to injections of LUVs, SUVs, or saline



"Mix" received SUVs on days 1, 3 & 5,
but also a dose of LUVs on day 3.
All other animals received single injections
on days 1, 3 & 5 (indicated by arrows).

FIG. 4

5/40

LDL receptor mRNA levels in liver in response
to injections of LUVs, SUVs, or saline




FIG. 5

6/40

LDL receptor mRNA levels in liver in response
to injections of LUVs, SUVs, or saline




FIG. 6

7/40

Cholesteryl ester transfer protein mRNA levels in liver
in response to injections of LUVs, SUVs, or saline




FIG. 7

8/40

7-alpha hydroxylase mRNA levels in liver in response
to injections of LUVs, SUVs, or saline




FIG. 8

*Indicates column of interest

9/40

Key points about LUV and atherosclerosis

1) Practical: Straight forward to manufacture
Non-toxic at very high doses

2) Mechanistic: Liposomes promote reverse
cholesterol transport *in vivo*

LUV are the optimal preparation

FIG. 9

10/40

Plasma unesterified cholesterol concentrations
in response to injections of LUV, SUV, or saline




FIG. 10

11/40

Plasma esterified cholesterol concentrations
in response to injections of LUV, SUV, or saline




FIG. 11

12/40

LDL esterified cholesterol concentrations
in response to injections of LUV, SUV, or saline




FIG. 12

13/40




FIG. 13

14/40

HDL esterified cholesterol concentrations
in response to injections of LUV, SUV, or saline




FIG. 14

15/40

HDL esterified cholesterol concentrations
in response to injections of LUV, SUV, or saline




FIG. 15

16/40




FIG. 16

17/40




FIG. 17

18/40

- Effectiveness in humans

- Therapeutic targets

Lipid-rich, rupture-prone plaques
Critical Stenosis
Post-angioplasty re-stenosis
Atherosclerosis in general

FIG. 18

19/40




FIG. 19

104030 224250

20/40




FIG. 20

21/40




FIG. 21

FIG. 21

22/40




FIG. 22

23/40




FIG. 23

Hepatic lipid contents in response to injections of LUVs, SUVs, or saline




FIG. 24

25/40




FIG. 25

26/40




FIG. 26

27/40




FIG. 27

28/40




FIG. 28

29/40




FIG. 29




FIG. 30

30/40




FIG. 31




FIG. 32

31/40




FIG. 33




FIG. 34

32/40




FIG. 35




FIG. 36

33/40




FIG. 37




FIG. 38

34/40




FIG. 39




FIG. 40

35/40




FIG. 41




FIG. 42

36/40




FIG. 43




FIG. 44

37/40




FIG. 45




FIG. 46

38/40




FIG. 47




FIG. 48

39/40




FIG. 49




FIG. 50

40/40




FIG. 51